

ASX: CVB

18 September 2026

Oversubscribed SPP Shortfall Offer and Placement raise \$1.75m to support CurveBeam AI's China expansion

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB) ("**CVB**", "**CurveBeam AI**" or the "**Company**"), a developer of point-of-care specialised medical imaging (CT) equipment and AI-enabled SaaS-based clinical assessment solutions, is pleased to announce the results of its Shortfall Offer under its share purchase plan ("**SPP**"), which was announced on Tuesday 4 August 2026.

The SPP was targeting A\$1m, with capacity to accept up to an additional A\$1m in oversubscriptions. This included a Shortfall Offer facility for any of the capacity not taken up by Eligible Shareholders, to be offered to investors by way of the Prospectus, whether or not they are existing shareholders.

The SPP offer closed on 28 August 2026, and the Company issued 33,675,039 (for a value of \$606,150.70) of the 111,111,111 ordinary shares that were contemplated as the maximum shares to be issued under the offer at a price of \$0.018 per share.

The Company engaged Spark Plus Pte Ltd (**Spark+**) as Corporate Advisor to fill the Shortfall Offer in a mandate dated 31 August 2026, and is pleased to advise that the offer was well oversubscribed by Australian and International investors with demand significantly exceeding the available Shortfall Offer capacity. The Company has elected to accept total demand through Spark+ of A\$1.75m, being A\$1.39m under the Shortfall Offer, and A\$0.36m as a placement at A\$0.018 per share consistent with the SPP offer. Further demand was scaled back due to the Company's available placement capacity.

Chief Executive Officer Greg Brown said: "We thank our new and existing shareholders for their continued support. The FDA 510(k) clearance of our CT based Bone Mineral Density (BMD) technology this week was an important milestone for CurveBeam AI and provides a strong regulatory foundation for the next stage of our strategy. We see significant potential to integrate bone quality assessment into both our weight bearing CT based imaging platforms and existing supine CT platforms. The Company is progressing commercial opportunities across China, the United States and other international markets. We look forward to updating shareholders as these opportunities develop.

The total funds of \$7.36m raised through the \$5m placement (at \$0.02 per share), \$0.61m SPP, and \$1.75m Shortfall Offer and further placement (at \$0.018 per share), will contribute to:

- Sales and marketing expenses including China market launch preparation for the HiRise™
- Research and development costs including product enhancements for the HiRise™
- Supply chain costs including preparing for China market launch
- Working capital and expenses of the offer

This announcement is authorised by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI Limited (ABN 32 140 706 618) (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

CEO and Managing Director:

Greg Brown
info@curvebeamai.com

Investor / media enquiries contact:

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

For personal use only